Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| GSK plc American Depositary Shares (Each representing two) | Belrestotug (EOS-448/GSK4428859A) - (TIG-006 mNSCLC, ENTRÉE) | 1L in advanced or metastatic Non-small cell lung cancer (NSCLC) | Phase 2 | Ongoing | Intravenous | Oncology |
| GSK plc American Depositary Shares (Each representing two) | Belrestotug (EOS-448/GSK4428859A) - (GALAXIES H&N-202) | PD-L1 positive recurrent / metastatic head and neck squamous cell carcinoma (HNSCC) | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| GSK plc American Depositary Shares (Each representing two) | Belrestotug + dostarlimab + GSK562 - (GSK6097608) | Advanced solid tumors | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| GSK plc American Depositary Shares (Each representing two) | AL101/GSK4527226 - (PROGRESS-AD) | Early Alzheimer's disease (AD) | Phase 2 | Ongoing | Oral | Neurology |
| GSK plc American Depositary Shares (Each representing two) | GSK4406371 (live, attenuated) | MMR (measles-mumps-rubella) Vacine (MMRVs) | Phase 2 | Ongoing | oral | Immunology |
| GSK plc American Depositary Shares (Each representing two) | Tebipenem pivoxil | cUTI | PDUFA | Ongoing | Oral | Antibiotic |
| GSK plc American Depositary Shares (Each representing two) | Jemperli (dostarlimab) plus chemotherapy - (PERLA) | Non-squamous non-small cell lung cancer (NSCLC) | Phase 2 | Trial Completed | Intravenous | Oncology |
| GSK plc American Depositary Shares (Each representing two) | Tebipenem pivoxil | cUTI | PDUFA | Ongoing | Oral | Antibiotic |
